Experimental data published on use of recommended medicines and treatments by NHS
Experimental data about the use of NICE recommended medicines and treatments by NHS organisations is today published by the Health and Social Care Information Centre (HSCIC) on behalf of the Department of Health (DH) and the NHS Commissioning Board (NHS CB).
NICE Technology Appraisals in the NHS in England 2011; Experimental Statistics – Innovation Scorecard; follows the Innovation Health and Wealth paper published by DH in 2011, which set out plans to support development and adoption of innovation in the NHS.
The publication presents limited data at organisational level about the use of medicines and medical technologies recommended for use in the NHS in England by the National Institute for Health and Clinical Excellence (NICE). It takes the form of an interactive spread-sheet and accompanying report, which describes the data and its limitations.
Although pointing towards variation between organisations and a valuable first step in assembling useful data, the information released today cannot be used to accurately consider adherence by individual organisations to NICE recommendations.
Variation is to be expected between organisations given the different sizes and needs of populations they serve and differing purchasing arrangements. Many NICE recommendations are also one of a number of options for treatment.
Data is shown for 76 medicines and six medical technologies covered by 102 technology appraisals; with the report comprising of four types of information:
Estimates of actual use and expected use of medicines (previously published in October 2012 as part of a separate report; Use of NICE-appraised medicines in the NHS in England – 2010 and 2011).
Volumes of medicines (used primarily in primary care) presented as defined daily dose per 100,000 of planned Clinical Commissioning Group (CCG) population.
Use of medical technologies in hospital trusts by the planned CCG of residence of the patient.
Volumes of medicines (used primarily in secondary care), presented as milligrams of drug purchased or provided by pharmaceutical companies by NHS trust per 100,000 hospital bed days (noting that this may not reflect actual use).
Classed as experimental, the report is an initial summary of available data, intended to generate discussion and feedback as to how best to further develop information in this area. It can be accessed at: www.ic.nhs.uk/pubs/niceapptech11.
Breaking local news as it happens, searchable archives with photographs, the ability to instantly comment on news articles – there are so many advantages to OTS (Onthespot) News.
If you want your news read locally online then send it to email@example.com – relying only on the newspaper is to restrict yourself to an ever reducing audience.
Onthespot – your online reporter www.onthespotnews.co.uk Do you have a story to tell?
Please text or phone 07930717137 or email firstname.lastname@example.org
Follow OTS (Onthespot) on Twitter www.twitter.com/onthespot_news